Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie JNJ-77242113 dotyczące leczenia uczestników cierpiących na umiarkowaną do ciężkiej łuszczycę plackowatą

2 lipca 2026 zaktualizowane przez: Janssen Research & Development, LLC

Wieloośrodkowe, randomizowane badanie III fazy z podwójnie ślepą próbą, kontrolowane placebo i kontrolowane aktywnym komparatorem deukrawacytynibu, mające na celu ocenę skuteczności i bezpieczeństwa JNJ-77242113 w leczeniu uczestników z umiarkowaną do ciężkiej łuszczycą plackowatą

Celem badania jest sprawdzenie skuteczności preparatu JNJ-77242113 u uczestników chorych na łuszczycę plackowatą o nasileniu umiarkowanym do ciężkiego w porównaniu z placebo i deukrawacytynibem.

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

774

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Argentyna
      • Buenos Aires, Argentyna, B1643CRO
        • Instituto Medico De Alta Complejidad (IMAC)
      • Buenos Aires, Argentyna, C1406AGA
        • ARCIS Salud SRL Aprillus asistencia e investigacion
      • CABA, Argentyna, C1425BEA
        • Instituto de Neumonología Y Dermatología
      • Caba, Argentyna, C1199ABD
        • Hospital Italiano de Buenos Aires
      • Caba, Argentyna, C1122AAF
        • Halitus Instituto Medico S.A. - Dermatologia y Estetica
      • La Plata, Argentyna, B1900AXI
        • Hospital Italiano de La Plata
      • Rosario, Argentyna, S2000PBJ
        • Instituto Caici Srl.
      • San Miguel de Tucumán, Argentyna, T4000AXL
        • Centro de investigaciones medicas Tucuman
  • Australia
      • Campbelltown, Australia, 5074
        • North Eastern Health Specialists
      • Canberra, Australia, 2606
        • Paratus Clinical Research Woden
      • East Melbourne, Australia, 3002
        • Sinclair Dermatology
      • Melbourne, Australia, 3053
        • Skin Health Institute Inc.
      • Woolloongabba, Australia, 4102
        • Veracity Clinical Research
  • Brazylia
      • Santo André, Brazylia, 09060-870
        • Fundacao do ABC Centro Universitario FMABC
  • Hiszpania
      • Alicante, Hiszpania, 03010
        • Hosp. Gral. Univ. Dr. Balmis
      • Barakaldo, Hiszpania, 48902
        • Hosp. Univ. de Cruces
      • Barcelona, Hiszpania, 08041
        • Hosp. de La Santa Creu I Sant Pau
      • Granada, Hiszpania, 18016
        • Hosp. Univ. San Cecilio
      • L'Hospitalet de Llobregat, Hiszpania, 08907
        • Hosp. Univ. de Bellvitge
      • Madrid, Hiszpania, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Hiszpania, 28007
        • Hosp. Gral. Univ. Gregorio Maranon
      • Madrid, Hiszpania, 28031
        • Hosp. Univ. Infanta Leonor
      • Madrid, Hiszpania, 28006
        • Hosp. Univ. de La Princesa
      • Madrid, Hiszpania, 28046
        • Hosp. Univ. de La Paz
      • Madrid, Hiszpania, 28002
        • Grupo Dermatologico Y Estetico Pedro Jaen
      • Valencia, Hiszpania, 46026
        • Hosp. Univ. I Politecni La Fe
  • Japonia
      • Fukuoka, Japonia, 814-0180
        • Fukuoka University Hospital
      • Fukutsu, Japonia, 811-3217
        • Hino Dermatology Clinic
      • Gifu, Japonia, 501-1112
        • Gifu University Hospital
      • Ginowan, Japonia, 901 2725
        • University of the Ryukyus hospital
      • Gunma, Japonia, 371 8511
        • Gunma University Hospital
      • Hokkaido, Japonia, 060-0033
        • JR Sapporo Hospital
      • Hokkaido, Japonia, 078 8510
        • Asahikawa Medical University Hospital
      • Isehara, Japonia, 259-1193
        • Tokai University Hospital
      • Itabashi Ku, Japonia, 173 8606
        • Teikyo University Hospital
      • Kawasaki, Japonia, 216 8511
        • St Marianna University Hospital
      • Kitakyushu-shi, Japonia, 807-8556
        • Hospital of the university of occupational and environmental health
      • Nagoya, Japonia, 467 8602
        • Nagoya City University Hospital
      • Nishiku, Japonia, 593-8324
        • Kume Clinic
      • Obihiro Shi, Japonia, 080 0013
        • Takagi Dermatological Clinic
      • Osaka, Japonia, 550 0006
        • Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital
      • Sakai, Japonia, 590 0197
        • Kindai University Hospital
      • Sapporo, Japonia, 060 0063
        • Sapporo Skin Clinic
      • Sendai, Japonia, 980 8574
        • Tohoku University Hospital
      • Suita, Japonia, 565 0871
        • The University of Osaka Hospital
      • Tachikawa, Japonia, 190 0023
        • Jitaikai Tachikawa dermatology clinic
      • Takaoka Shi, Japonia, 933-0871
        • Shirasaki dermatology clinic
      • Tokyo, Japonia, 160-0023
        • Tokyo Medical University Hospital
      • Tsu, Japonia, 514 8507
        • Mie University Hospital
  • Kanada
    • British Columbia
      • Surrey, British Columbia, Kanada, V3V 0C6
        • Enverus Medical
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Kanada, A1A 4Y3
        • Karma Clinical Trials Inc.
    • Ontario
      • Ajax, Ontario, Kanada, L1S7K8
        • CCA Medical Research Corporation
      • Barrie, Ontario, Kanada, L4M 7G1
        • SimcoDerm Medical and Surgical Dermatology Centre
      • Hamilton, Ontario, Kanada, L8N 1Y2
        • Dermatrials Research
      • Richmond Hill, Ontario, Kanada, L4B1L1
        • York Dermatology Clinic and Research Centre
      • Waterloo, Ontario, Kanada, N2J 1C4
        • Alliance Clinical Trials
      • Windsor, Ontario, Kanada, N8T 1E6
        • XLR8 Medical Research
  • Korea Południowa
      • Busan, Korea Południowa, 49241
        • Pusan National University Hospital
      • Seongnam-si, Korea Południowa, 13620
        • Seoul National University Bundang Hospital
      • Seoul, Korea Południowa, 03080
        • Seoul National University Hospital
      • Seoul, Korea Południowa, 06591
        • The Catholic University of Korea Seoul St Marys Hospital
      • Seoul, Korea Południowa, 05030
        • Konkuk University Medical Center
      • Seoul, Korea Południowa, 04763
        • Hanyang University Medical Center
      • Seoul, Korea Południowa, 130 050
        • Kyung Hee University Hospital
  • Niemcy
      • Berlin, Niemcy, 10789
        • ISA - Interdisciplinary Study Association GmbH
      • Bramsche, Niemcy, 49565
        • Hautarztpraxis 3
      • Dresden, Niemcy, 01069
        • Klinische Forschung Dresden GmbH
      • Dresden, Niemcy, 01097
        • Praxis fuer Dermatologie und Venerologie
      • Düsseldorf, Niemcy, 40225
        • Universitaetsklinikum Duesseldorf
      • Hamburg, Niemcy, 22391
        • MensingDerma Research GmbH
      • Hamburg, Niemcy, 20246
        • Universitaetsklinikum Hamburg Eppendorf
      • Kiel, Niemcy, 24105
        • Universitaetsklinikum Schleswig Holstein Campus Kiel
      • Langenau, Niemcy, 89129
        • Studienzentrum Dr Schwarz Germany
      • Leipzig, Niemcy, 04103
        • Universitätsklinikum Leipzig AöR
      • Lübeck, Niemcy, 23562
        • Universitatsklinikum Schleswig Holstein Campus Lubeck
      • Mannheim, Niemcy, 68167
        • Universitaetsklinikum Mannheim
      • München, Niemcy, 80802
        • Klinik und Poliklinik fur Dermatologie und Allergologie am Biederstein
      • Potsdam, Niemcy, 14467
        • Hautarztpraxis 1
      • Rostock, Niemcy, 18057
        • Universitaetsmedizin Rostock
  • Polska
      • Bialystok, Polska, 15-351
        • Osteo-Medic s.c A. Racewicz, J Supronik
      • Bialystok, Polska, 15-375
        • Specderm Poznanska sp j
      • Elblag, Polska, 82 300
        • Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
      • Krakow, Polska, 31-411
        • Centrum Medyczne PROMED
      • Krakow, Polska, 30 438
        • Centrum Medyczne dr Rajzer Sp z o o
      • Krakow, Polska, 30-002
        • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
      • Lodz, Polska, 90-338
        • Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna
      • Lodz, Polska, 90-265
        • Dermed Centrum Medyczne Sp z o o
      • Osielsko, Polska, 86031
        • Dermodent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski S C
      • Poznan, Polska, 61 731
        • Clinical Research Center sp z o o MEDIC R s k
      • Poznan, Polska, 60 529
        • SOLUMED Centrum Medyczne
      • Warsaw, Polska, 02 953
        • Klinika Ambroziak Dermatologia
      • Warsaw, Polska, 01 817
        • Dorota Bystrzanowska High-Med. Przychodnia Specjalistyczna
      • Wroclaw, Polska, 51 503
        • DERMMEDICA Sp.z o.o.
      • Wroclaw, Polska, 52 416
        • Centrum Medyczne Oporow
      • Wroclaw, Polska, 51 685
        • Wro Medica
  • Stany Zjednoczone
    • Arizona
      • Phoenix, Arizona, Stany Zjednoczone, 85006
        • Medical Dermatology Specialists
      • Scottsdale, Arizona, Stany Zjednoczone, 85260
        • Center for Dermatology and Plastic Surgery
    • Arkansas
      • Fort Smith, Arkansas, Stany Zjednoczone, 72916
        • Johnson Dermatology
    • California
      • Fountain Valley, California, Stany Zjednoczone, 92708
        • First Oc Dermatology
      • Fremont, California, Stany Zjednoczone, 94538
        • Center for Dermatology Clinical Research
      • Sacramento, California, Stany Zjednoczone, 95815
        • Integrative Skin Science and Research
      • Santa Ana, California, Stany Zjednoczone, 92701
        • Southern California Dermatology
      • Santa Monica, California, Stany Zjednoczone, 90403
        • Clinical Science Institute
    • Florida
      • Miami, Florida, Stany Zjednoczone, 33126
        • Driven Research LLC
      • North Miami Beach, Florida, Stany Zjednoczone, 33162
        • Ziaderm Research LLC
      • Ocala, Florida, Stany Zjednoczone, 34470
        • Renstar Medical Research
      • Tampa, Florida, Stany Zjednoczone, 33613
        • Forcare Clinical Research Inc
    • Georgia
      • Alpharetta, Georgia, Stany Zjednoczone, 30022
        • Hamilton Research LLC
      • Macon, Georgia, Stany Zjednoczone, 31217
        • Skin Care Physicians Of Georgia
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60602
        • DeNova Research
      • Rolling Meadows, Illinois, Stany Zjednoczone, 60008
        • Arlington Dermatology
      • Skokie, Illinois, Stany Zjednoczone, 60077
        • Endeavor Health
      • West Dundee, Illinois, Stany Zjednoczone, 60118
        • Dundee Dermatology
    • Indiana
      • Indianapolis, Indiana, Stany Zjednoczone, 46250
        • Dawes Fretzin Clinical Research Group LLC
      • Plainfield, Indiana, Stany Zjednoczone, 46168
        • Indiana Clinical Trial Center
    • Kentucky
      • Louisville, Kentucky, Stany Zjednoczone, 40241
        • Dermatology Specialists
    • Louisiana
      • Lake Charles, Louisiana, Stany Zjednoczone, 70605
        • Dermatology and Advanced Aesthetics
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02111
        • Tufts Medical Center
    • Michigan
      • Ann Arbor, Michigan, Stany Zjednoczone, 48103
        • David Fivenson MD, Dermatology
      • Clarkston, Michigan, Stany Zjednoczone, 48346
        • Michigan Center of Medical Research
      • Detroit, Michigan, Stany Zjednoczone, 48202
        • Henry Ford Medical Center
      • Fort Gratiot, Michigan, Stany Zjednoczone, 48059
        • Hamzavi Dermatology
    • Missouri
      • Saint Joseph, Missouri, Stany Zjednoczone, 64506
        • Medisearch Clinical Trials
    • Nebraska
      • Omaha, Nebraska, Stany Zjednoczone, 68144
        • Skin Specialists
    • Nevada
      • Las Vegas, Nevada, Stany Zjednoczone, 89119
        • Fife Dermatology
    • New Hampshire
      • Portsmouth, New Hampshire, Stany Zjednoczone, 03801
        • StracSkin
    • New Jersey
      • East Windsor, New Jersey, Stany Zjednoczone, 08520
        • Schweiger Dermatology Group
      • Hackensack, New Jersey, Stany Zjednoczone, 07601
        • Schweiger Dermatology Group 1
    • New York
      • Stony Brook, New York, Stany Zjednoczone, 11790
        • Derm Research Center of New York, Inc.
    • North Carolina
      • Wilmington, North Carolina, Stany Zjednoczone, 28405
        • Wilmington Dermatology Center
    • Ohio
      • Athens, Ohio, Stany Zjednoczone, 45701
        • Oakview Dermatology
      • Boardman, Ohio, Stany Zjednoczone, 44512
        • Optima Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73170
        • Central Sooner Research
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97201
        • Oregon Medical Research Center
    • South Dakota
      • Rapid City, South Dakota, Stany Zjednoczone, 57702
        • Health Concepts
    • Texas
      • Dallas, Texas, Stany Zjednoczone, 75231
        • Modern Research Associates
      • Houston, Texas, Stany Zjednoczone, 77004
        • Center for Clinical Studies 1
      • Houston, Texas, Stany Zjednoczone, 77056
        • Austin Institute for Clinical Research 1
      • Pflugerville, Texas, Stany Zjednoczone, 78660
        • Austin Institute for Clinical Research
      • San Antonio, Texas, Stany Zjednoczone, 78218
        • Texas Dermatology and Laser Specialists
      • San Antonio, Texas, Stany Zjednoczone, 78213
        • Progressive Clinical Research
      • Webster, Texas, Stany Zjednoczone, 77598
        • Center for Clinical Studies
    • Virginia
      • Richmond, Virginia, Stany Zjednoczone, 23294
        • National Clinical Research
    • Washington
      • Mill Creek, Washington, Stany Zjednoczone, 98012
        • Frontier Derm Partners CRO, LLC
      • Spokane, Washington, Stany Zjednoczone, 99202
        • Premier Clinical Research
  • Tajwan
      • Hsinchu, Tajwan, 30059
        • National Taiwan University Hospital Hsin Chu Branch
      • Kaohsiung City, Tajwan, 833
        • Chang Kung Memorial Hospital
      • New Taipei City, Tajwan, 235
        • Taipei Medical University Shuang Ho Hospital
      • Taipei, Tajwan, 112
        • Taipei Veterans General Hospital
      • Taipei, Tajwan, 10048
        • National Taiwan University Hospital
      • Taipei, Tajwan, 10449
        • Taipei Mackay Memorial Hospital
      • Taoyuan, Tajwan, 33382
        • Linkou Chang Gung Memorial Hospital
  • Węgry
      • Borgyogyaszati Klinika, Węgry, 7632
        • Pécsi Tudományegyetem
      • Budapest, Węgry, 1036
        • Obudai Egeszsegugyi Centrum Kft
      • Debrecen, Węgry, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Debrecen, Węgry, 4031
        • Derma-B Kft
      • Kaposvár, Węgry, 7400
        • Somogy Varmegyei Kaposi Mor Oktato Korhaz
      • Szeged, Węgry, 6720
        • SZTE AOK Szent-Gyorgyi Albert Klinikai Kozpont, Borgyogyaszati és Allergologiai Klinika
      • Szolnok, Węgry, 5000
        • Allergo-Derm Bakos Kft.
      • Veszprém, Węgry, 8200
        • Medmare Egeszsegugyi Es Szolgaltato Bt.
  • Zjednoczone Królestwo
      • London, Zjednoczone Królestwo, SE1 9RT
        • Guys and St Thomas NHS Foundation Trust
      • Reading, Zjednoczone Królestwo, RG1 5AN
        • Royal Berkshire Hospital
      • Salford, Zjednoczone Królestwo, M6 8HD
        • Salford Royal Hospital
      • Southampton, Zjednoczone Królestwo, SO16 6YD
        • University Hospital Southampton NHS Foundation Trust

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Kryteria przyjęcia:

  • Rozpoznanie łuszczycy plackowatej z lub bez łuszczycowego zapalenia stawów (ŁZS) przez co najmniej 26 tygodni przed pierwszym podaniem badanego leku
  • Całkowita powierzchnia ciała (BSA) większa lub równa (>=) 10 procent (%) w badaniu przesiewowym i na początku
  • Całkowita powierzchnia łuszczycy i wskaźnik nasilenia (PASI) >=12 w badaniu przesiewowym i na początku badania
  • Całkowita ogólna ocena badacza (IGA) >=3 podczas badania przesiewowego i na początku badania
  • Kandydat do fototerapii lub leczenia systemowego łuszczycy plackowatej

Kryteria wyłączenia:

  • Niepłytkowa postać łuszczycy (na przykład erytrodermia, kropelkowata lub krostkowa)
  • Aktualna łuszczyca polekowa (na przykład nowy początek łuszczycy lub zaostrzenie łuszczycy po zastosowaniu beta-blokerów, blokerów kanału wapniowego lub litu)
  • Aktualna diagnoza lub oznaki lub objawy ciężkich, postępujących lub niekontrolowanych zaburzeń nerek, wątroby, serca, naczyń, płuc, przewodu pokarmowego, endokrynologii, neurologii, hematologii, reumatologii, psychiatrii lub metabolizmu
  • Znane alergie, nadwrażliwość lub nietolerancja na JNJ-77242113 lub jego substancje pomocnicze
  • Poważny zabieg chirurgiczny (na przykład wymagający znieczulenia ogólnego) w ciągu 8 tygodni przed badaniem przesiewowym lub nie nastąpi w pełni powrót do zdrowia po zabiegu chirurgicznym lub zabieg chirurgiczny jest zaplanowany w czasie, w którym uczestnik ma wziąć udział w badaniu

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: JNJ-77242113
Uczestnicy otrzymają JNJ-77242113 od tygodnia 0 do 156 tygodnia i deukrawacytynib odpowiadające placebo od tygodnia 0 do 24 tygodnia.
Lek: JNJ-77242113
JNJ-77242113 będzie podawany doustnie.
Lek: Deukrawacytynib Dopasowanie Placebo
Placebo odpowiadające deukrawacytynibowi będzie podawane doustnie.
Komparator placebo: Placebo
Uczestnicy otrzymają odpowiadające placebo dla leku JNJ-77242113 od 0 do 16 tygodnia, pasujące placebo dla deukrawacytynibu od tygodnia 0 do 24 tygodnia i JNJ-77242113 od 16 do 156 tygodnia.
Lek: JNJ-77242113
JNJ-77242113 będzie podawany doustnie.
Lek: JNJ-77242113 Dopasowane placebo
Odpowiednie placebo JNJ-77242113 będzie podawane doustnie.
Lek: Deukrawacytynib Dopasowanie Placebo
Placebo odpowiadające deukrawacytynibowi będzie podawane doustnie.
Aktywny komparator: Deukrawacytynib
Uczestnicy otrzymają deukrawacytynib od tygodnia 0 do tygodnia 24 oraz odpowiadające placebo JNJ-77242113 od tygodnia 0 do tygodnia 24 i JNJ-77242113 od tygodnia 24 do tygodnia 156.
Lek: JNJ-77242113
JNJ-77242113 będzie podawany doustnie.
Lek: JNJ-77242113 Dopasowane placebo
Odpowiednie placebo JNJ-77242113 będzie podawane doustnie.
Lek: Deukrawacytynib
Deukrawacytynib będzie podawany doustnie.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16
Ramy czasowe: Week 16
IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema, scaling, each using 5 point scale. Induration:0=no evidence of plaque elevation, 1=minimal plaque elevation,=0.25 millimeters(mm); 2=mild plaque elevation,=0.5 mm; 3=moderate plaque elevation,=0.75 mm; 4=severe plaque elevation,>1 mm; Erythema: 0=no evidence of erythema, hyperpigmentation may be present, 1=faint erythema, 2=light red coloration, 3=moderate red coloration, 4=bright red coloration; Scaling: 0=no evidence of scaling, 1=minimal; occasional fine scale over less than 5% of lesion, 2=mild; fine scale dominates, 3=moderate; coarse scale predominates, 4=severe; thick, scale predominates. Final IGA score was based upon average of induration, erythema and scaling scores assessed on 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe(4). Higher score=more severe disease. Baseline=closest measurement taken prior to or at time of first study drug administration date.
Week 16
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16
Ramy czasowe: Week 16
Percentage of participants who achieved PASI-90 score (>=90% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change From Baseline in Body Surface Area (BSA) at Week 16
Ramy czasowe: Baseline (Week 0), Week 16
A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1% BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Baseline (Week 0), Week 16
Percentage of Participants Who Achieved IGA Score of 0 at Week 16
Ramy czasowe: Week 16
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, >1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
Week 16
Percentage of Participants Who Achieved Psoriasis Symptom and Signs Diary (PSSD) Symptom Score of 0 at Weeks 8 and 16 Among Participants With a Baseline PSSD Symptom Score >0
Ramy czasowe: Weeks 8 and 16
PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Symptom score was derived by averaging the 5 weekly symptom item scores when at least 3 items are available (>=50% of 5 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Weeks 8 and 16
Percentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Weeks 4 and 16 Among Participants With a Baseline PSSD Itch Score >=4
Ramy czasowe: Weeks 4 and 16
PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. PSSD itch item score over seven days was averaged into a weekly itch score, ranging from 0 to 10 with higher scores indicating severe disease. Baseline=closest measurement taken prior to or at time of first study drug administration date.
Weeks 4 and 16
Percentage of Participants Who Achieved an IGA Score of 0 at Weeks 16 and 24
Ramy czasowe: Weeks 16 and 24
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, >1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
Weeks 16 and 24
Percentage of Participants Who Achieved PSSD Sign Score of 0 at Week 16 Among Participants With a Baseline Sign Score >0
Ramy czasowe: Week 16
PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Sign score was derived by averaging the 6 weekly sign item scores when at least 3 items are available (>=50% of 6 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percentage of Participants Who Achieved Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 Among Participants With a Baseline GenPS-SFQ Item 2 Score >=2 and With a Baseline sPGA-G Score >=3
Ramy czasowe: Week 16
The GenPs-SFQ was a 2-item participant-reported instrument used to assess the impact of genital psoriasis on the frequency of sexual activity in the last 7 days. Item 1 assesses overall frequency of sexual activity in the last 7 days (none/zero, once, or 2 or more times), and item 2 assesses how frequently genital psoriasis symptoms have limited the frequency of sexual activity in the last 7 days (0 = never, 1 = rarely, 2 = sometimes, 3 = often, or 4 = always). Lower scores of item 2 indicated less limitation of sexual activity due to genital psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percentage of Participants Who Achieved Dermatological Life Quality Index (DLQI) Score of 0 or 1 at Week 16 Among Participants With a Baseline DLQI Score >1
Ramy czasowe: Week 16
The DLQI was a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much, where higher score indicated more impact on QoL). The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percentage of Participants Who Achieved DLQI Score of 0 or 1 at Weeks 16 and 24 Among Participants With a Baseline DLQI Score >1
Ramy czasowe: Weeks 16 and 24
The DLQI was a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much, where higher score indicated more impact on QoL). The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Weeks 16 and 24
Percentage of Participants Who Achieved PASI 75 at Weeks 4 and 16
Ramy czasowe: Weeks 4 and 16
Percentage of participants who achieved PASI-75 score (>=75% improvement from baseline in PASI) at Weeks 4 and 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Weeks 4 and 16
Percentage of Participants Who Achieved PASI 90 at Week 8
Ramy czasowe: Week 8
Percentage of participants who achieved PASI-90 score (>=90% improvement from baseline in PASI) at Week 8 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 8
Percentage of Participants Who Achieved PASI 100 at Week 16
Ramy czasowe: Week 16
Percentage of participants who achieved PASI-100 score (100% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percentage of Participants Who Achieved a Scalp Specific (ss)-IGA Score of 0 or 1 and >=2-Grade Improvement From Baseline at Week 16 Among Participants With a Baseline Ss-IGA Score >=2
Ramy czasowe: Week 16
The ss-IGA instrument was used to evaluate the disease severity of scalp psoriasis. The lesions were assessed in terms of the clinical signs of redness, thickness, and scaliness which was scored as: absence of disease = 0, very mild disease = 1, mild disease = 2, moderate disease = 3, and severe disease = 4. A higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percentage of Participants Who Achieved an IGA Score of 0 or 1 and >=2-Grade Improvement From Baseline at Weeks 16 and 24
Ramy czasowe: Weeks 16 and 24
IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0=no evidence of plaque elevation, 1=minimal plaque elevation, =0.25 mm; 2=mild plaque elevation, =0.5 mm; 3=moderate plaque elevation, =0.75 mm; 4=severe plaque elevation, >1 mm; Erythema: 0=no evidence of erythema, hyperpigmentation may be present, 1=faint erythema, 2=light red coloration, 3=moderate red coloration, 4=bright red coloration; Scaling: 0=no evidence of scaling, 1=minimal; occasional fine scale over <5% of lesion, 2=mild; fine scale dominates, 3=moderate; coarse scale predominates, 4=severe; thick, scale predominates. Final IGA score of psoriasis was based upon average of induration, erythema and scaling scores assessed on 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score=more severe disease. Baseline=closest measurement taken prior to or at time of first study drug administration date.
Weeks 16 and 24
Percentage of Participants Who Achieved PASI 75 at Weeks 16 and 24
Ramy czasowe: Weeks 16 and 24
Percentage of participants who achieved PASI-75 score (>=75% improvement from baseline in PASI) at Weeks 16 and 24 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Weeks 16 and 24
Percentage of Participants Who Achieved PASI 90 at Weeks 16 and 24
Ramy czasowe: Weeks 16 and 24
Percentage of participants who achieved PASI-90 score (>=90% improvement from baseline in PASI) at Weeks 16 and 24 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Weeks 16 and 24
Percentage of Participants Who Achieved PASI 100 at Weeks 16 and 24
Ramy czasowe: Weeks 16 and 24
Percentage of participants who achieved PASI-100 score (100% improvement from baseline in PASI) at Weeks 16 and 24 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Weeks 16 and 24
Percentage of Participants Who Achieved PSSD Symptom Score of 0 at Week 16 Among Participants With a Baseline Symptom Score >0
Ramy czasowe: Week 16
PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Symptom score was derived by averaging the 5 weekly symptom item scores when at least 3 items are available (>=50% of 5 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date
Week 16
Change From Baseline in PASI Total Score at Week 16
Ramy czasowe: Baseline (Week 0), Week 16
Change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Baseline (Week 0), Week 16
Percent Change From Baseline in PASI Total Score at Week 16
Ramy czasowe: Baseline (Week 0), Week 16
Percent change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Baseline (Week 0), Week 16
Percentage of Participants Who Achieved Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 and a >=2-grade Improvement at Week 16 Among Participants With a Baseline sPGA-G Score >=2
Ramy czasowe: Week 16
The sPGA-G was a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis was assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5). Higher score indicates more severity. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percentage of Participants Who Achieved Physician's Global Assessment of Hands and Feet (Hf-PGA) Score of 0 or 1 and a >=2-grade Improvement at Week 16 Among Participants With a Baseline Hf-PGA Score >=2
Ramy czasowe: Week 16
The hf-PGA assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet. hf-PFA was categorized from 0 to 4 where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher score indicates more severity. Meeting the hf-PGA 0 or 1 criteria defined as having an hf-PGA score of clear (0) or almost clear (1) and a >=2-grade improvement from baseline. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percent Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 16 Among Participants With a Baseline mNAPSI Score >0
Ramy czasowe: Baseline (Week 0), Week 16
Percent change from baseline in mNAPSI score at week 16 was reported. The mNAPSI was an index used for assessing and grading the severity of nail psoriasis. Each of the participant's ten fingernails were evaluated on 7 features. The first three features were each scored from 0 to 3 in severity and were 1 = onycholysis and oil-drop dyschromia, 2 = pitting, and 3 = nail plate crumbling. Next four features was each scored 0 absent or 1 present, and are (1) leukonychia, (2) splinter hemorrhages (3) nail bed hyperkeratosis, and (4) red spots in lunula. Each fingernail was rated for the presence and severity of seven features to give a total fingernail score of 0-13 (0= no involvement, 13 = greatest involvement). Total mNAPSI score is the sum of the 10 fingernail scores (range 0-130; 0= no involvement, 130= greatest involvement). Higher the score the more severe the nail bed psoriasis. Baseline = closest measurement taken prior to or at the time of the first study drug administration date.
Baseline (Week 0), Week 16
Percentage of Participants Who Achieved Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16 Among Participants With Baseline f-PGA Score >=2
Ramy czasowe: Week 16
Percentage of participants who achieved f-PGA score of 0 or 1 at Week 16 was reported. f-PGA 0 or 1 criteria was defined as an f-PGA score of clear (0) or minimal (1). The f-PGA is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Change From Baseline in PSSD Symptom Score at Week 16
Ramy czasowe: Baseline (Week 0), Week 16
Change from baseline in PSSD symptoms score at Week 16 was reported. PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Symptom score was derived by averaging the 5 weekly symptom item scores when at least 3 items are available (>=50% of 5 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date
Baseline (Week 0), Week 16
Change From Baseline in PSSD Sign Score at Week 16
Ramy czasowe: Baseline (Week 0), Week 16
Change from baseline in PSSD sign score at Week 16 was reported. PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Sign score was derived by averaging the 6 weekly sign item scores when at least 3 items are available (>=50% of 6 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Baseline (Week 0), Week 16
Change From Baseline in Total DLQI Score at Week 16
Ramy czasowe: Baseline (Week 0), Week 16
Change from baseline in total DLQI score at Week 16 was reported. The DLQI was a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much, where higher score indicated more impact on QoL). The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Baseline (Week 0), Week 16
Change From Baseline in Domain Scores of the Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Score at Week 16
Ramy czasowe: Baseline (Week 0), Week 16
PROMIS-29, 29-item generic HRQoL survey, assesses each 7 PROMIS domains (depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; ability to participate in social roles and activities) with 4 questions and pain intensity. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often and 5=always). Pain intensity was rated on 11-point scale (0=no pain; 10=worst imaginable pain). Higher score= worst pain. Each domain included 4 items, plus a single pain intensity item totaling 29 items. Raw score of each PROMIS domain was converted into a standardized score with mean of 50; standard deviation (SD) of 10 (T-Score). Higher PROMIS T-score=more of concept being measured i.e. higher scores in anxiety, depression, fatigue, pain interference, sleep disturbance= worse symptoms, higher scores in physical function, social roles= better functioning. Baseline: closest measurement taken prior to/at the time of first study drug administration date.
Baseline (Week 0), Week 16
Percentage of Participants Who Achieved PSSD Symptom Score of 0 at Week 24 Among Participants With Baseline Symptom Score >0
Ramy czasowe: Week 24
PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Symptom score was derived by averaging the 5 weekly symptom item scores when at least 3 items are available (>=50% of 5 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date
Week 24
Percentage of Participants Who Achieved PASI 75 After Week 24, Among PASI 75 Nonresponders to Deucravacitinib at Week 24
Ramy czasowe: Week 24 up to Week 160
Week 24 up to Week 160
Percentage of Participants Who Achieved PASI 90 After Week 24, Among PASI 90 Nonresponders to Deucravacitinib at Week 24
Ramy czasowe: Week 24 up to Week 160
Week 24 up to Week 160
Percentage of Participants Who Achieved IGA Score of 0 or 1 After Week 24, Among Participants in the Deucravacitinib Group With IGA Score >=2 at Week 24
Ramy czasowe: Week 24 up to Week 160
Week 24 up to Week 160
Number of Participants With Adverse Events (AEs)
Ramy czasowe: From Week 0 to Week 160
From Week 0 to Week 160
Number of Participants With Serious Adverse Events (SAEs)
Ramy czasowe: From Week 0 to Week 160
From Week 0 to Week 160

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Janssen Research & Development, LLC

Śledczy

  • Dyrektor Studium: Janssen Research & Development, LLC Clinicaltrial, Janssen Research & Development, LLC

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

1 lutego 2024

Zakończenie podstawowe (Rzeczywisty)

17 września 2024

Ukończenie studiów (Szacowany)

1 czerwca 2027

Daty rejestracji na studia

Pierwszy przesłany

14 listopada 2023

Pierwszy przesłany, który spełnia kryteria kontroli jakości

16 listopada 2023

Pierwszy wysłany (Rzeczywisty)

22 listopada 2023

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

7 lipca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 lipca 2026

Ostatnia weryfikacja

1 lipca 2026

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • 77242113PSO3002 (Inny identyfikator: Janssen Research & Development, LLC)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Polityka udostępniania danych Janssen Pharmaceutical Companies należącej do Johnson & Johnson jest dostępna pod adresem www.janssen.com/clinical-trials/transparency. Jak wskazano na tej stronie, wnioski o dostęp do danych z badania można składać za pośrednictwem witryny projektu Yale Open Data Access (YODA) pod adresem yoda.yale.edu

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj